Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSDI Group Regulatory News (SDI)

Share Price Information for SDI Group (SDI)

Share Price is delayed by 15 minutes
Get Live Data
82.00    -1.40 (-1.68%)
Bid:
81.00
Ask:
83.00
Spread: 2.00 (2.469%)
Market Cap: £85.75m
SDI Live PriceLast checked at - London Stock Exchange

Intraday SDI Group Share Chart

Synbiosis Update

28 Jun 2010 07:00

RNS Number : 1395O
Scientific Digital Imaging Plc
28 June 2010
Β 

ο»Ώ

Β 

Β 

SCIENTIFIC DIGITAL IMAGING PLC

Β 

("SDI" or "The Group")

Β 

Β 

SYNBIOSIS INTRODUCES NEW IMAGING ACCESSORY, ProcUV,

AND

IMPROVEMENTS ARE MADE TO ProtoCOL2

Β 

SDI, theΒ AIMΒ quoted group focused on the needs of the scientific community, is pleased to update the market regarding recent developments at Synbiosis, a core division of SDI's principal subsidiary Synoptics Ltd. ("Synoptics"), a developer and manufacturer of innovative scientific instruments and systems that exploit digital imaging technology for a range of disciplines.

Β 

Highlights

Β 

Β·; ProtoCOL2 automated colony counter has been extensively tested to enable rapid, accurate counts of Legionella on any Legionella detection media

Β·; ProtoCOL2 upgraded to allow rapid statistical analysis of flu and bacterial vaccine potency and antibiotics susceptibility testing results

Β·; Synbiosis has introduced ProcUV, a new UV imaging accessory for the ProtoCOL2 system

Β 

Β 

At Synbiosis, the world-leading manufacturer of automated microbiological systems, the innovative ProtoCOL2 automated colony counter has been extensively tested by the Synbiosis technical team to enable rapid, accurate counts of Legionella on any Legionella detection media. The team found that by using the ProtoCOL2 system, 600Legionella plates could be accurately processed per hour, which is approximately 30 times more than can be achieved using traditional, time consuming, error-prone manual techniques.

Β 

The ProtoCOL2 has also been upgraded to allow rapid statistical analysis of flu and bacterial vaccine potency and antibiotics susceptibility testing results. The ProtoCOL2 software has also been upgraded so that numerical data can be automatically transferred into programmes for statistical analysis saving scientists valuable time and preventing transcription errors, as data can be transferred via a single button click rather than manually entered.

Β 

Additionally, Synbiosis has introduced ProcUV, its new ultra-violet imaging accessory for the ProtoCOL2 system. ProcUV permits instant imaging of fluorescent colonies and plaques so that they can be automatically counted or analysed by ProtoCOL2, thus saving time and improving accuracy of results.

Β 

ProcUV is simple to set up as its automatic exposure time settings ensure users can capture colony images at the touch of a button. The high-quality images can then be directly transferred into the ProtoCOL2 in seconds, where the ProtoCOL2 counts and analyses results automatically, to save microbiologists countless hours of repetitive work.

Β 

Commenting on the progress SDI's Chairman, Harry Tee, said:

Β 

"Synbiosis' progress with ProcUV and ProtoCOL2 demonstrates that we have risen to the challenge of rapid and accurate quantification of some of the most difficult-to-count colonies. We continue to look at new and innovative ways to improve our product offering to meet the needs of the scientific community."

Β 

Β 

Β 

--END--

Β 

Β 

FOR FURTHER INFORMATION

Β 

Scientific Digital Imaging plc 01223 727144

Harry Tee CBE, Chairman

Phil Atkin, CEO

www.scientificdigitalimaging.comΒ 

Β 

Bishopsgate Communications 020 7562 3350

Gemma O'Hara

Siobhra Murphy

sdi@bishopsgatecommunications.comΒ 

Β 

Β 

Β 

Β 

Note to Editors

Β 

Β 

Scientific Digital Imaging plc

Β 

SDI plc is focused on the application of digital imaging technology to the needs of the scientific community.

Β 

The principal subsidiary is Synoptics, which designs and manufactures special-purpose instruments for use in the life sciences.Β In October 2008 SDI acquired the entire share capital of Artemis and Perseu, companies (now known as "Atik") that design and manufacture high-sensitivity cameras for both astronomical and life sciences applications and whose products are used in instruments manufactured by Synoptics.

Β 

SDI, through its subsidiaries, offers a range of digital imaging solutions and intends to acquire other companies that are capable of contributing one or more key elements to the solutions required including an in-depth understanding of the applications in the marketplace, the ability to engineer complete systems to address such applications and the provision of key, high-performance components such as cameras.www.scientificdigitalimaging.com

Β 

Β 

Synoptics Ltd

Β 

Synoptics develops and manufactures innovative scientific instruments and systems that exploit digital imaging technology for a range of disciplines. Synoptics offers its products through 3 divisions.

Β 

Β·; Syngene - produces equipment for life scientists to image and analyse electrophoresis gels used for DNA and protein analysis.

Β·; Synbiosis - produces equipment for microbiologists to automate microbial colony counting.

Β·; Syncroscopy - provides systems which apply digital imaging techniques to microscopy applications, such as life and material sciences.

Β 

The Synoptics strategy is to deliver world-class, innovative products that satisfy the real needs of customers in science and industry.Β It does this by understanding their demands, and using its component technologies and skills in image processing and analysis to engineer appropriate solutions.Β The Company also seeks to exploit its unique technologies directly, by establishing OEM partnerships with other companies. www.synoptics.co.uk

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
NRAZXLFLBQFXBBD
Date   Source Headline
10th Jun 20267:00 amRNSDirectorate change
21st May 20267:00 amRNSTrading Update
11th May 20261:00 pmRNSDirectorate change
10th Apr 20264:40 pmRNSHolding(s) in Company
9th Apr 20265:05 pmRNSHolding(s) in Company
20th Mar 202610:45 amRNSHolding(s) in Company
17th Mar 20267:00 amRNS-RNews from Portfolio Companies
17th Mar 20267:00 amRNS-RNews from Portfolio Companies
13th Mar 20261:41 pmRNSHolding(s) in Company
2nd Mar 20266:00 pmRNSDirector/PDMR Shareholding
23rd Feb 20263:45 pmRNSHolding(s) in Company
13th Feb 20267:00 amRNSAcquisition of PRP Optoelectronics
3rd Dec 20257:00 amRNSInterim Results
17th Nov 20257:00 amRNSNotice of Results and Investor Presentation
7th Oct 20254:49 pmRNSAIM Rule 17 and Schedule 2(g) Update
6th Oct 20257:00 amRNSAppointment of Joint Corporate Broker
25th Sep 20257:00 amRNSGrant of Share Option Awards
24th Sep 20252:30 pmRNSResult of AGM
24th Sep 20257:00 amRNSAGM Trading Update
19th Sep 20253:31 pmRNSHolding(s) in Company
21st Aug 20257:00 amRNSPosting of Annual Report and Notice of AGM
30th Jul 20257:00 amRNSFinal Results
21st Jul 20257:00 amRNSNotice of Results and Investor Presentation
26th Jun 20252:14 pmRNSAIM Rule 17 and Schedule 2(g) Update
6th Jun 20257:00 amRNSAcquisition of Severn Thermal Solutions
19th May 20257:00 amRNSTrading Update
6th May 20257:00 amRNS-RInspecVision awarded King's Award for Enterprise
11th Apr 20253:00 pmRNSHolding(s) in Company
4th Apr 20251:55 pmRNSDirector / PDMR Shareholding
4th Apr 20257:00 amRNSAcquisition of Collins Walker
20th Mar 20257:00 amRNS-RNews from Portfolio Companies
14th Mar 20257:00 amRNSDirector/PDMR Shareholding
5th Dec 20247:00 amRNSInterim Results
14th Nov 20247:00 amRNSNotice of Results and Investor Presentation
30th Oct 20247:00 amRNSAcquisition of InspecVision
14th Oct 202410:00 amRNSHoldings in Company
7th Oct 20245:00 pmRNSHolding(s) in Company
27th Sep 20247:00 amRNSShare Option Awards
26th Sep 20243:00 pmRNSDirector/PDMR Shareholding
26th Sep 20241:05 pmRNSResult of AGM
26th Sep 20247:00 amRNSAGM Trading Update
28th Aug 20247:00 amRNSPosting of Annual Report & Accounts & AGM Notice
30th Jul 20247:00 amRNSFinal Results
23rd Jul 20241:00 pmRNSNotice of Results and Investor Presentation
4th Jul 202411:45 amRNSHolding(s) in Company
3rd Jul 20244:25 pmRNSHolding(s) in Company
23rd May 202411:30 amRNSHolding(s) in Company
20th May 20247:00 amRNSTrading Update
3rd Apr 20242:15 pmRNSExercise of Share Options and Total Voting Rights
18th Mar 202412:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.